Literature DB >> 29806214

Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection.

Katarina Tomovic1, Jelena Lazarevic2, Gordana Kocic3, Marina Deljanin-Ilic4, Marko Anderluh5, Andrija Smelcerovic2.   

Abstract

Dipeptidyl peptidase-4 (DPP-4) cleaves N-terminal dipeptides, with Pro, Ala or Ser at the penultimate position, and, in that way, modulates biological activity of certain polypeptides. Due to its ubiquitous distribution, many pathological processes are associated with altered DPP-4 expression and activity. Besides the regulation of glucose metabolism, DPP-4 also exhibits many other systemic effects, and the inhibition of its activity might lead to cardiovascular and renal protection. Mechanisms underlying these protective effects of DPP-4 inhibition are ascribed to elevated bioavailability of its substrates, to impacts on mediators and signaling pathways that ameliorate cardiovascular and renal function through the suppression of oxidative stress, inflammation, fibrosis and apoptosis, improved endothelial function and tissue reparation. Inflammation contributes to and promotes progression of cardiovascular and renal disorders. Herein, we discuss cellular and molecular mechanisms mediating the anti-inflammatory activity of clinically used DPP-4 inhibitors in cardiovascular and renal protection.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiovascular protection; dipeptidyl peptidase-4 inhibitor; inflammation; renoprotection

Mesh:

Substances:

Year:  2018        PMID: 29806214     DOI: 10.1002/med.21513

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  13 in total

1.  DPP-4 as a Novel Biomarker for Inflammatory Bowel Disease: Is It Ready for Clinical Use?

Authors:  Courtney Perry; Neeraj Kapur; Terrence A Barrett
Journal:  Inflamm Bowel Dis       Date:  2020-10-23       Impact factor: 5.325

Review 2.  Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?

Authors:  Petr Busek; Jonathan S Duke-Cohan; Aleksi Sedo
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

Review 3.  Epicardial Adipose Tissue and Cardiac Arrhythmias: Focus on Atrial Fibrillation.

Authors:  Maddalena Conte; Laura Petraglia; Serena Cabaro; Vincenza Valerio; Paolo Poggio; Emanuele Pilato; Emilio Attena; Vincenzo Russo; Adele Ferro; Pietro Formisano; Dario Leosco; Valentina Parisi
Journal:  Front Cardiovasc Med       Date:  2022-06-30

4.  Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial.

Authors:  Hiroki Teragawa; Takeshi Morimoto; Yuichi Fujii; Tomohiro Ueda; Mio Sakuma; Michio Shimabukuro; Osamu Arasaki; Koichi Node; Takashi Nomiyama; Shinichiro Ueda
Journal:  Diabetes Metab Syndr Obes       Date:  2020-12-15       Impact factor: 3.168

5.  Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.

Authors:  Sang Youl Rhee; Jeongwoo Lee; Hyewon Nam; Dae-Sung Kyoung; Dong Wook Shin; Dae Jung Kim
Journal:  Diabetes Metab J       Date:  2021-03-05       Impact factor: 5.376

6.  The Impact of Incretin-Based Medications on Lipid Metabolism.

Authors:  Habib Yaribeygi; Mina Maleki; Alexandra E Butler; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2021-12-29       Impact factor: 4.011

7.  Vildagliptin, a dipeptidyl peptidase-4 inhibitor, attenuated endothelial dysfunction through miRNAs in diabetic rats.

Authors:  Qian Zhang; Xinhua Xiao; Jia Zheng; Ming Li; Miao Yu; Fan Ping; Tong Wang; Xiaojing Wang
Journal:  Arch Med Sci       Date:  2019-07-12       Impact factor: 3.318

8.  Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways.

Authors:  Nami Lee; Yu Jung Heo; Sung-E Choi; Ja Young Jeon; Seung Jin Han; Dae Jung Kim; Yup Kang; Kwan Woo Lee; Hae Jin Kim
Journal:  J Immunol Res       Date:  2021-06-02       Impact factor: 4.818

9.  Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 - A systematic review and meta-analysis.

Authors:  Ahmad Fariz Malvi Zamzam Zein; Wilson Matthew Raffaello
Journal:  Prim Care Diabetes       Date:  2021-12-13       Impact factor: 2.459

Review 10.  Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review.

Authors:  Michał Konwerski; Aleksandra Gąsecka; Grzegorz Opolski; Marcin Grabowski; Tomasz Mazurek
Journal:  Biology (Basel)       Date:  2022-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.